# OnCo record c-144-01 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/c-144-01/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "c-144-01", "NCT02360579" ;
  schema:name "C-144-01"@en ;
  schema:description "The single-arm study that got the first cell therapy for a solid tumour approved: one in three patients responded after everything else had failed."@en ;
  schema:url <https://onco.cc/trials/c-144-01/> ;
  schema:dateModified "2026-09-07"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT02360579> ;
  onco:status "positive" ;
  onco:phase "2" ;
  schema:startDate "2015-09-24" ;
  onco:cancers <https://onco.cc/cancers/melanoma/>, <https://onco.cc/cancers/advanced-melanoma/> ;
  onco:technologies <https://onco.cc/technologies/til-therapy/> ;
  onco:drugs <https://onco.cc/drugs/lifileucel/> ;
  onco:companies <https://onco.cc/companies/iovance/> ;
  onco:people <https://onco.cc/people/amod-sarnaik/> .